IN2012DN00954A - - Google Patents

Info

Publication number
IN2012DN00954A
IN2012DN00954A IN954DEN2012A IN2012DN00954A IN 2012DN00954 A IN2012DN00954 A IN 2012DN00954A IN 954DEN2012 A IN954DEN2012 A IN 954DEN2012A IN 2012DN00954 A IN2012DN00954 A IN 2012DN00954A
Authority
IN
India
Prior art keywords
compound
methyl
salt
tablet
content
Prior art date
Application number
Inventor
Murakawa Yusuke
Okabe Takayuki
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43529294&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2012DN00954(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of IN2012DN00954A publication Critical patent/IN2012DN00954A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

Provided is a tablet having a high content of 2—[[6— [ (3R)-3-amino-l-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-4-fluorobenzonitrile (compound (A)) or a salt thereof as a pharmaceutically active component. A tablet containing compound (A) or a salt thereof, and a fluidizer, which has a compound (A) content of 35 - 50 weight%.
IN954DEN2012 2009-07-28 2010-07-27 IN2012DN00954A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009175695 2009-07-28
PCT/JP2010/062568 WO2011013639A1 (en) 2009-07-28 2010-07-27 Tablet

Publications (1)

Publication Number Publication Date
IN2012DN00954A true IN2012DN00954A (en) 2015-04-10

Family

ID=43529294

Family Applications (1)

Application Number Title Priority Date Filing Date
IN954DEN2012 IN2012DN00954A (en) 2009-07-28 2010-07-27

Country Status (23)

Country Link
US (1) US20120129878A1 (en)
EP (1) EP2460523B1 (en)
JP (1) JP5732394B2 (en)
KR (1) KR20120039046A (en)
CN (1) CN102548556A (en)
AU (1) AU2010279171A1 (en)
BR (1) BR112012001959A2 (en)
CA (1) CA2769177A1 (en)
CL (1) CL2012000182A1 (en)
CO (1) CO6612226A2 (en)
CR (1) CR20120061A (en)
EA (1) EA201270204A1 (en)
EC (1) ECSP12011699A (en)
IL (1) IL217560A0 (en)
IN (1) IN2012DN00954A (en)
MA (1) MA33539B1 (en)
MX (1) MX2012001284A (en)
PE (1) PE20120919A1 (en)
SG (1) SG178062A1 (en)
TN (1) TN2012000031A1 (en)
TW (1) TW201106991A (en)
WO (1) WO2011013639A1 (en)
ZA (1) ZA201200761B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5874545B2 (en) * 2011-06-20 2016-03-02 アステラス製薬株式会社 Pharmaceutical composition for oral administration
JP6122879B2 (en) 2012-06-05 2017-04-26 武田薬品工業株式会社 Solid preparation
CN103768071B (en) * 2012-10-23 2016-08-17 中国医药工业研究总院 A kind of oral formulations treating diabetes
CN103877054B (en) * 2012-12-21 2016-05-25 北大方正集团有限公司 A kind of SYR-322 tablet and preparation method thereof
CN105078974A (en) * 2014-05-23 2015-11-25 深圳信立泰药业股份有限公司 Allisartan isoproxil solid dispersion and pharmaceutical composition
US20160331689A1 (en) * 2015-05-12 2016-11-17 SE Tylose USA, Inc. Aqueous enteric coating composition
CN105596341B (en) * 2016-03-14 2018-08-10 石家庄四药有限公司 A kind of amber love song Ge Lieting solid pharmaceutical preparations and preparation method
WO2017195796A1 (en) 2016-05-10 2017-11-16 日本臓器製薬株式会社 Method for manufacturing acetaminophen preparation
CN114122219A (en) * 2020-08-28 2022-03-01 群创光电股份有限公司 Light emitting unit
CN116763752B (en) * 2023-08-24 2023-11-17 北京福元医药股份有限公司 Acarbose tablet and preparation method thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585115A (en) * 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
WO1997010224A1 (en) 1995-09-13 1997-03-20 Takeda Chemical Industries, Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
JP2711528B2 (en) * 1995-12-20 1998-02-10 大洋薬品工業株式会社 Loxoprofen preparation
AR035016A1 (en) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd COMPOSITION OF AZOL PROMOTER OF PRODUCTION / SECRETION OF NEUROTROFINE, COMPOSITE PRODROGA OF THE SAME, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND USE OF THE SAME TO PREPARE THIS LAST.
WO2002006234A1 (en) 2000-07-17 2002-01-24 Takeda Chemical Industries, Ltd. Sulfone derivatives, process for their production and use thereof
TW200416029A (en) 2002-11-01 2004-09-01 Takeda Chemical Industries Ltd Agent for preventing or treating neuropathy
AU2003277576A1 (en) 2002-11-08 2004-06-07 Takeda Pharmaceutical Company Limited Receptor function controlling agent
US20070004736A1 (en) 2002-11-22 2007-01-04 Keiji Kubo Imidazole derivative, process for producing the same, and use
EP1630152A4 (en) 2003-05-30 2009-09-23 Takeda Pharmaceutical Condensed ring compound
WO2005030740A1 (en) 2003-09-30 2005-04-07 Takeda Pharmaceutical Company Limited Thiazoline derivative and use of the same
US7820673B2 (en) 2003-12-17 2010-10-26 Takeda Pharmaceutical Company Limited Urea derivative, process for producing the same, and use
BRPI0418148A (en) 2003-12-25 2007-04-17 Takeda Pharmaceutical compound, prodrug of a compound, gpr40 receptor function modulator, pharmaceutical agent, use of a compound and methods of modifying a gpr40 receptor function in a mammal, prophylaxis or treating diabetes in a mammal and producing a compound
WO2005063725A1 (en) 2003-12-26 2005-07-14 Takeda Pharmaceutical Company Limited Phenylpropanoic acid derivatives
NZ549716A (en) 2004-03-15 2010-04-30 Takeda Pharmaceutical Pyrimidin-dione derivatives as dipeptidyl peptidase inhibitors
JP4875978B2 (en) 2004-03-15 2012-02-15 武田薬品工業株式会社 Aminophenylpropanoic acid derivatives
JP4859665B2 (en) 2004-03-30 2012-01-25 武田薬品工業株式会社 Alkoxyphenylpropanoic acid derivatives
TWI396686B (en) 2004-05-21 2013-05-21 Takeda Pharmaceutical Cyclic amide derivative, and its production and use
JP4919252B2 (en) * 2004-08-05 2012-04-18 株式会社明治 Granular preparation and method for producing the same
EP2308839B1 (en) 2005-04-20 2017-03-01 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
ES2434072T3 (en) * 2005-06-09 2013-12-13 Norgine Bv Solid preparation of 2-hexadecyloxy-6-methyl-4H-3,1-benzoxacin-4-one
JP5084503B2 (en) 2005-07-29 2012-11-28 武田薬品工業株式会社 Cyclopropanecarboxylic acid compound
JPWO2007013694A1 (en) 2005-07-29 2009-02-12 武田薬品工業株式会社 Phenoxyalkanoic acid compound
TW200740435A (en) 2005-08-10 2007-11-01 Takeda Pharmaceuticals Co Therapeutic agent for diabetes
JP2007063225A (en) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd Imidazopyridine compound
JP2007211005A (en) * 2006-01-16 2007-08-23 Ono Pharmaceut Co Ltd Composition for solid preparation and solid preparation
RS52307B (en) 2006-06-27 2012-12-31 Takeda Pharmaceutical Company Limited Fused cyclic compounds
KR20090088854A (en) 2006-09-13 2009-08-20 다케다 야쿠힌 고교 가부시키가이샤 Administration of dipeptidyl peptidase inhibitors
US8492405B2 (en) 2006-10-18 2013-07-23 Takeda Pharmaceutical Company Limited Glucokinase-activating fused heterocyclic compounds and methods of treating diabetes and obesity
KR101444486B1 (en) 2006-10-19 2014-09-24 다케다 야쿠힌 고교 가부시키가이샤 Indole compound
EP2128138A1 (en) 2007-01-29 2009-12-02 Takeda Pharmaceutical Company Limited Pyrazole compound
PE20081734A1 (en) * 2007-02-01 2009-01-19 Takeda Pharmaceutical TABLET COMPARING 2 - [[6 - [(3R) -3-AMINO-1-PIPERIDINYL] -3,4-DIHYDRO-3-METHYL-2,4-DIOXO-1 (2H) -PYRIMIDINYL] METHYL] -BENZONITRILE AND MICROCRYSTALLINE CELLULOSE
EA200970746A1 (en) 2007-02-09 2010-02-26 Такеда Фармасьютикал Компани Лимитед CONDENSED CYCLIC COMPOUNDS AS PARTIAL PPAR-GAMMA AGONISTS
US7994183B2 (en) * 2007-03-13 2011-08-09 Takeda Pharmaceutical Company Limited Solid preparation comprising 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-4-fluorobenzonitrile
US8318746B2 (en) 2007-04-27 2012-11-27 Takeda Pharmaceutical Company Limited Nitrogen-containing five-membered heterocyclic compound
WO2008156757A1 (en) 2007-06-19 2008-12-24 Takeda Pharmaceutical Company Limited Indazole compounds for activating glucokinase
US8400391B2 (en) 2008-01-10 2013-03-19 Honeywell International Inc. Method and system for improving dimming performance in a field sequential color display device

Also Published As

Publication number Publication date
CN102548556A (en) 2012-07-04
JPWO2011013639A1 (en) 2013-01-07
CA2769177A1 (en) 2011-02-03
CR20120061A (en) 2012-03-06
EP2460523A1 (en) 2012-06-06
CO6612226A2 (en) 2013-02-01
EA201270204A1 (en) 2012-08-30
WO2011013639A1 (en) 2011-02-03
AU2010279171A1 (en) 2012-03-01
TN2012000031A1 (en) 2013-09-19
JP5732394B2 (en) 2015-06-10
BR112012001959A2 (en) 2016-03-15
CL2012000182A1 (en) 2012-10-12
EP2460523B1 (en) 2017-01-04
MX2012001284A (en) 2012-03-26
ECSP12011699A (en) 2012-03-30
SG178062A1 (en) 2012-03-29
US20120129878A1 (en) 2012-05-24
EP2460523A4 (en) 2014-02-26
TW201106991A (en) 2011-03-01
IL217560A0 (en) 2012-02-29
MA33539B1 (en) 2012-08-01
ZA201200761B (en) 2013-05-29
KR20120039046A (en) 2012-04-24
PE20120919A1 (en) 2012-08-13

Similar Documents

Publication Publication Date Title
IN2012DN00954A (en)
TW200612958A (en) Substituted imidazole derivatives
TW200801000A (en) Spiroindolinone derivatives
MX2009009703A (en) Solid preparation comprising 2- [ [6- [ (3r) -3-amino-1-piperidin yl] -3, 4-dihydr0-3-methyl-2, 4-di0x0-1 (2h) -pyrimidinyl] methyl] -4-fluorobenzonitrile.
MX2007004699A (en) Indole and benzimidazole derivatives.
MX2010004576A (en) Novel pyrimidine derivatives.
HK1154002A1 (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
JO2761B1 (en) 1Phenyl-2-Pyridinyl Alkyl Alcohol Derivatives As Phosphodiesterase Inhibitors
MX2009004746A (en) 1,2,4-triazole derivatives as sigma receptor inhibitors.
TN2010000044A1 (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
WO2009082152A3 (en) Glucokinase activators and pharmaceutical compositions containing the same as an active ingredient
MY151295A (en) Pyrimidyl indoline compound
MX2011012523A (en) Ketal esters of anhydropentitols and uses thereof.
HRP20080493T3 (en) Substituted quinoline derivatives as mitotic kinesin inhibitors
UA104885C2 (en) Isothiazolyloxyphenyl amidines and use thereof as fungicides
UA105229C2 (en) Pharmaceutical formulation
MY147188A (en) Substituted imidazole compounds as ksp inhibitors
TN2009000287A1 (en) Cyclized derivatives as eg-5inhibitors
GEP20156242B (en) 2-arylimidazole derivatives as pde10a enzyme inhibitors
MY161461A (en) Akt and p70 s6 kinase inhibitors
MY148732A (en) Triazolium salts as par1 inhibitors, production thereof, and use as medicaments
WO2009097973A3 (en) Imidazopyridazines as par1 inhibitors, production thereof, and use thereof as medicaments
MX2009006266A (en) Processes for the preparation of 3-(4-(2,4-difluorobenzyloxy)-3-b romo-6-methyl-2-oxopyridin-1(2h)-yl)-n,4-dimethylbenzamide.
MY153733A (en) Novel quinazoline-2,4-dione derivative, and medical compositions for the prophylaxis and treatment of cranial nerve disease containing the same
TW200531693A (en) Prolonged-release diuretic compositions